VRTX250404P560000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $462 From $459, Keeps Equalweight Rating
Vertex Pharmaceuticals Price Target Raised to $462 From $459 at Morgan Stanley
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Long Term Growth Stock to Buy According to Billionaires?
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?
Press Release: Vertex to Announce First Quarter 2025 Financial Results on May 5th
Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis
Vertex's Journavx Launch Sparks Optimism, Analyst Sees 'Two Potential Upside Levers'
Express News | European Commission Approves Expanded Label for Kaftrio® in Combination With Ivacaftor for People With Cystic Fibrosis
European Commission Approves Expanded Label for KAFTRIO in Combination With Ivacaftor for People With Cystic Fibrosis
Vertex to Announce First Quarter 2025 Financial Results on May 5th
11 Stocks to Buy After the Biotech Bloodbath -- -2-
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Wells Fargo Remains a Hold on Vertex Pharmaceuticals (VRTX)
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
Is Vertex Pharmaceuticals Gaining or Losing Market Support?
Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
CVS, COR, Among Top S&P 500 Healthcare Gainers in Q1; WST and MRNA Among Losers
Nasdaq 100 Logs Worst Quarter in Three Years - Here's What's Driving the Drop